Search Contact
AB-BIOTICS preventive measures for Coronavirus – Covid-19
Since Thursday 12th of March, AB-BIOTICS team is working from home, following recommended SARS-CoV-2 containing measures. The company has implemented measures to ensure all business areas have full access to servers and information; moreover, all the facilities that AB-BIOTICS works with are reporting business as usual. Hence all schedules and operations are unaffected....
Read More
Patients with mental health problems treated with Neurofarmagen experience a reduction in adverse effects and respond to treatment quicker and more effectively
The Christmas holidays that have just passed were a cause for celebration for many people, but for many others it could have contributed to the worsening of pathologies such as depression or anxiety. That is why it is essential not to abandon treatments and have the additional help of medical professionals who...
Read More
AB-Biotics organizes a round table in Moscow to discuss new probiotic treatments for Upper Respiratory Tract Infections
The  “V Federal Annual Forum Of Otolaryngologists With International Participation. Multidisciplinary Approach To Head And Neck Treatment” took place last 19th to 20th of September in Moscow, as an international and interdisciplinary forum where specialists discussed latest trends and research in the field of Otolaryngology. One of the round tables of the...
Read More
The Company’s Board of Directors agreed to the delisting of all the shares from the Alternative Stock Market
On November 22nd, the Company’s Board of Directors agreed to the delisting of all the shares representing the capital stock of AB-BIOTICS, SA from the Alternative Stock Market, as well as the delegation of powers in favour of the Executive Directors to the aforementioned effects, so that they may act on behalf...
Read More
Kaneka takes over 86.6% of AB-Biotics’ share capital
AB-Biotics has announced, as a relevant fact, that the offer to acquire shares of Kaneka, in the context of the delisting of the Spanish company, has been accepted by 2,292. 426 shares, an amount that represents 57.62% of the shares to the offerees and 18.21% of the company's share capital. In addition,...
Read More
AB-Biotics launches a psychobiotic that reduces stress and anxiety
AB-Biotics and Kaneka Probiotics were active participants at the Probiota Asia congress held in Singapore between October 22nd and 24th, organized by NutraIngredients-Asia. This annual event focuses on the  pharmaceutical and food industry market for probiotics, prebiotics and microbiota. AB-Biotics, together with its main shareholder, Kaneka Probiotics, played a leading role, thanks...
Read More
AB-Biotics & Kaneka Probiotics visited Probiota Asia in Singapore
This event took place in Singapore, on October between 22th and 24th.  This is a forum focused in prebiotic, probiotic and microbiota which scientists and delegates from food and pharma industries are the main visitors,  to uncover business opportunities, stimulate innovation and drive collaboration. AB-Biotics & Kaneka Probiotics had a leading role...
Read More
Eighty-two percent of the shareholders from AB-Biotics approve of the exclusion of the company from the Alternative Stock Market
AB-Biotics celebrates at the Stock market of Barcelona an Extraordinary Shareholders Meeting which approved the proposal to exclude from the negotiation all of the company’s shares in the Alternative Stock Market. The Board counted with an assistance of shareholders who possess 96.5% of the social capital of the company. The 82.06% voted...
Read More
AB-Biotics presents biannual benefits for the first time
AB-Biotics has published the biannual accounts for the fiscal year 2019 where it has presented a positive result of 772,000 euros, against a loss of 377,000 from the first semester of last year, which means that this is the first semester that ever presents profits in its history. Furthermore, during the first...
Read More